Dr Siccardi is currently an Associate Professor in the Department of Pharmacology and Therapeutics at the University of Liverpool. He graduated with an MSc in Clinical Biology (2006) from the University of Turin, Italy. He obtained his PhD at the University of Liverpool, Liverpool, UK (2011) focusing his research on molecular mechanisms influencing drug distribution and predictors of exposure in patients. He has authored >70 peer reviewed publications, presenting his findings at several national and international congresses.
His research interests focus on the optimisation of novel nanomedicine and traditional formulations for drug delivery based on experimental pharmacological data from in silico, in vitro and in vivo models, aiming to improve pharmacokinetics, efficacy and side effects. He is interested in the clarification of the ADME processes involved in drug disposition and the identification of nanoformulation characteristics influencing drug exposure. He is actively involved in the development of physiologically based pharmacokinetic models to predict drug and nanomedicine distribution to inform the development process and the optimisation of clinical scenarios.
Conflict of Interest: I received research grants from Janssen and ViiV. I also serve as a consultant to Merck, Resolution Therapeutics and Nevakar Inc.